Shuiying Hu

4.8k total citations
94 papers, 3.5k citations indexed

About

Shuiying Hu is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Shuiying Hu has authored 94 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 32 papers in Molecular Biology and 23 papers in Hematology. Recurrent topics in Shuiying Hu's work include Drug Transport and Resistance Mechanisms (44 papers), Pharmacogenetics and Drug Metabolism (17 papers) and Cancer Treatment and Pharmacology (16 papers). Shuiying Hu is often cited by papers focused on Drug Transport and Resistance Mechanisms (44 papers), Pharmacogenetics and Drug Metabolism (17 papers) and Cancer Treatment and Pharmacology (16 papers). Shuiying Hu collaborates with scholars based in United States, Netherlands and Italy. Shuiying Hu's co-authors include Alex Sparreboom, Sharyn D. Baker, Mingzhao Xing, Shelley Orwick, Alice A. Gibson, Dingxie Liu, Peng Hou, Vasily Vasko, Lie Li and Ryan M. Franke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Nature Communications.

In The Last Decade

Shuiying Hu

89 papers receiving 3.4k citations

Peers

Countries citing papers authored by Shuiying Hu

Since Specialization

Citations

This map shows the geographic impact of Shuiying Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuiying Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuiying Hu more than expected).

Fields of papers citing papers by Shuiying Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuiying Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuiying Hu. The network helps show where Shuiying Hu may publish in the future.

Co-authorship network of co-authors of Shuiying Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Shuiying Hu. A scholar is included among the top collaborators of Shuiying Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuiying Hu. Shuiying Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Strain-dependent neuronal disposition and toxicity of paclitaxel in mice 2025 ·(unknown), Yue Xu, Eman Ahmed, (unknown), (unknown), (unknown), Kevin M. Huang, Alex Sparreboom, Shuiying Hu, Leah M. Pyter, Eric D. Eisenmann	1
2	Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice 2025 ·Molecules ·(unknown), Eman Ahmed, Peng Hu, Alex Sparreboom, Shuiying Hu	1
3	Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen 2024 ·Cancer Research Communications ·(unknown), (unknown), (unknown), Kevin M. Huang, Peter de Bruijn, Mahesh R. Nepal, Josie A. Silvaroli, (unknown), Eric D. Eisenmann, Xiaolin Cheng, Navjotsingh Pabla, Ron H.J. Mathijssen, Sharyn D. Baker, Shuiying Hu, Alex Sparreboom, Zahra Talebi	2
4	Darolutamide does not interfere with OATP‐mediated uptake of docetaxel 2024 ·International Journal of Cancer ·(unknown), Zahra Talebi, (unknown), Yan Jin, Alice A. Gibson, Peng Hu, Peter de Bruijn, Corrina M.A. de Ridder, Debra Stuurman, Shuiying Hu, Wytske M. van Weerden, Stijn L.W. Koolen, Ronald de Wit, Alex Sparreboom, Ron H.J. Mathijssen, Eric D. Eisenmann	3
5	Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity 2022 ·Cancer Research Communications ·Mahesh R. Nepal, (unknown), Yang Li, Zahra Talebi, Muhammad Erfan Uddin, Yan Jin, (unknown), Alice A. Gibson, Maryam B. Lustberg, Shuiying Hu, Alex Sparreboom	7
6	Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B 2022 ·Molecules ·(unknown), Yan Jin, Zahra Talebi, Shuiying Hu, Alex Sparreboom, Sharyn D. Baker, Eric D. Eisenmann	5
7	A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities 2022 ·Pharmaceutics ·Yang Li, Yan Jin, (unknown), Keith T. Schmidt, Alice A. Gibson, (unknown), Eric D. Eisenmann, Ron H.J. Mathijssen, William D. Figg, Sharyn D. Baker, Alex Sparreboom, Shuiying Hu	5
8	Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation 2021 ·Clinical Cancer Research ·(unknown), Mingqing Chen, (unknown), Alice A. Gibson, (unknown), Shichen Shen, Jun Qu, Su Sien Ong, Taosheng Chen, Yan Jin, Muhammad Erfan Uddin, Kevin M. Huang, Aviv Paz, Alex Sparreboom, Shuiying Hu, Jason A. Sprowl	27
9	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions 2020 ·Reviews of physiology, biochemistry and pharmacology ·(unknown), Kevin M. Huang, Maryam B. Lustberg, Alex Sparreboom, Shuiying Hu	7
10	Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy 2019 ·Materials Science and Engineering C ·Pankaj Dwivedi, (unknown), (unknown), Rong Fan, Anil Kumar Dwivedi, Zhiqiang Zhu, Fangsheng Huang, Qiang Wu, Renuka Khatik, David E. Cohn, Ting Si, Shuiying Hu, Alex Sparreboom, Ronald X. Xu	26
11	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues 2017 ·Cancer Research ·Christina D. Drenberg, Alice A. Gibson, Stanley Pounds, Lei Shi, (unknown), Lie Li, Shuiying Hu, Guoqing Du, Anne T. Nies, Matthias Schwab, Navjotsingh Pabla, William Blum, Tanja A. Grüber, Sharyn D. Baker, Alex Sparreboom	46
12	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death 2016 ·Cancer Research ·Eric I. Zimmerman, Alice A. Gibson, Shuiying Hu, Aksana Vasilyeva, Shelley Orwick, Guoqing Du, (unknown), Su Sien Ong, Taosheng Chen, Peter Vogel, Hiroto Inaba, Michael L. Maitland, Alex Sparreboom, Sharyn D. Baker	38
13	Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel 2014 ·Cancer Research ·Annemieke J.M. Nieuweboer, Shuiying Hu, Chunshan Gui, Bruno Hagenbuch, (unknown), Alice A. Gibson, Peter de Bruijn, Ron H.J. Mathijssen, Alex Sparreboom	47
14	Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide 2013 ·Clinical Cancer Research ·Eric I. Zimmerman, Shuiying Hu, (unknown), Alice A. Gibson, Shelley Orwick, Lie Li, Alex Sparreboom, Sharyn D. Baker	131
15	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1) 2013 ·Clinical Cancer Research ·Anne T. Nies, Elke Schaeffeler, Heiko van der Kuip, Ingolf Cascorbi, Oliver Bruhn, Michael Kneba, Christiane Pott, Ute Hofmann, Christopher Volk, Shuiying Hu, Sharyn D. Baker, Alex Sparreboom, Peter Ruth, Hermann Koepsell, Matthias Schwab	52
16	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel 2012 ·Clinical Cancer Research ·Anne‐Joy M. de Graan, Cynthia S. Lancaster, Amanda Obaidat, Bruno Hagenbuch, Laure Elens, Lena E. Friberg, Peter de Bruijn, Shuiying Hu, Alice A. Gibson, Gitte Hoffmann Bruun, Thomas J. Corydon, Torben Stamm Mikkelsen, Aisha L. Walker, Guoqing Du, Walter J. Loos, Ron H. N. van Schaik, Sharyn D. Baker, Ron H.J. Mathijssen, Alex Sparreboom	76
17	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide 2012 ·Molecular Cancer Therapeutics ·Chaoxin Hu, Cynthia S. Lancaster, Zhili Zuo, Shuiying Hu, Zhaoyuan Chen, Jeffrey E. Rubnitz, Sharyn D. Baker, Alex Sparreboom	54
18	Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters 2009 ·Clinical Cancer Research ·Shuiying Hu, Zhaoyuan Chen, Ryan M. Franke, Shelley Orwick, Ming Zhao, Michelle A. Rudek, Alex Sparreboom, Sharyn D. Baker	129
19	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia 2008 ·Molecular Cancer Therapeutics ·Shuiying Hu, Hongmei Niu, (unknown), Shelley Orwick, Akira Shimada, Hiroto Inaba, Gary V. Dahl, Jeffrey E. Rubnitz, Sharyn D. Baker	31
20	Phosphatidylinositol 3-Kinase/Akt Positively Regulates Fas (CD95)-Mediated Apoptosis in Epidermal Cl41 Cells 2006 ·The Journal of Immunology ·Bin Lü, Liying Wang, Christian Stehlik, (unknown), Chuanshu Huang, Shuiying Hu, Fei Chen, Xianglin Shi, Yon Rojanasakul	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact